U.S. Capital Wealth Advisors LLC cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) by 4.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,738 shares of the pharmaceutical company's stock after selling 669 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Vertex Pharmaceuticals were worth $4,435,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Humankind Investments LLC boosted its stake in shares of Vertex Pharmaceuticals by 1.9% during the second quarter. Humankind Investments LLC now owns 1,836 shares of the pharmaceutical company's stock valued at $517,000 after acquiring an additional 35 shares during the last quarter. Procyon Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 2.8% in the 2nd quarter. Procyon Advisors LLC now owns 1,366 shares of the pharmaceutical company's stock worth $385,000 after purchasing an additional 37 shares during the last quarter. Zions Bancorporation N.A. raised its stake in Vertex Pharmaceuticals by 5.2% during the 2nd quarter. Zions Bancorporation N.A. now owns 753 shares of the pharmaceutical company's stock valued at $212,000 after acquiring an additional 37 shares in the last quarter. Nkcfo LLC raised its stake in shares of Vertex Pharmaceuticals by 0.5% in the 2nd quarter. Nkcfo LLC now owns 8,515 shares of the pharmaceutical company's stock worth $2,399,000 after buying an additional 40 shares in the last quarter. Finally, TFC Financial Management raised its stake in shares of Vertex Pharmaceuticals by 58.0% in the 2nd quarter. TFC Financial Management now owns 109 shares of the pharmaceutical company's stock worth $31,000 after buying an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 91.33% of the company's stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Bastiano Sanna sold 1,791 shares of the business's stock in a transaction dated Tuesday, October 18th. The stock was sold at an average price of $300.31, for a total value of $537,855.21. Following the completion of the sale, the executive vice president now owns 39,192 shares of the company's stock, valued at $11,769,749.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Vertex Pharmaceuticals news, EVP David Altshuler sold 1,303 shares of the business's stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $303.04, for a total value of $394,861.12. Following the completion of the sale, the executive vice president now owns 36,077 shares of the company's stock, valued at $10,932,774.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Bastiano Sanna sold 1,791 shares of the business's stock in a transaction dated Tuesday, October 18th. The stock was sold at an average price of $300.31, for a total value of $537,855.21. Following the transaction, the executive vice president now directly owns 39,192 shares of the company's stock, valued at approximately $11,769,749.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,715 shares of company stock valued at $1,125,226. Insiders own 0.40% of the company's stock.

Vertex Pharmaceuticals Price Performance

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on VRTX. HC Wainwright boosted their price objective on Vertex Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research note on Friday, August 5th. JPMorgan Chase & Co. boosted their price objective on Vertex Pharmaceuticals from $319.00 to $327.00 and gave the stock an "overweight" rating in a research note on Monday, October 24th. Argus lifted their target price on Vertex Pharmaceuticals from $320.00 to $340.00 and gave the stock a "buy" rating in a report on Thursday, November 17th. Cowen lifted their target price on Vertex Pharmaceuticals from $315.00 to $330.00 in a report on Friday, October 28th. Finally, Royal Bank of Canada lifted their target price on Vertex Pharmaceuticals from $281.00 to $288.00 and gave the stock a "sector perform" rating in a report on Friday, October 28th. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $305.33.

Vertex Pharmaceuticals Company Profile

(Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Further Reading

• Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
• MarketBeat: Week in Review 11/21 – 11/25
• Is the 60/40 Portfolio Mix Still in Vogue?
• Microsoft Shares: Is it Time to Back Up the Truck?
• Three CBD Stocks to Dominate a Budding Industry
• Institutional Support for Analog Devices Remains High

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating).

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.